Direxion Daily S&P Biotech Bull 3X Shares (LABU)
| Assets | $765.55M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 8.07M |
| Dividend (ttm) | $0.31 |
| Dividend Yield | 0.34% |
| Ex-Dividend Date | Jun 25, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | -28.53% |
| Volume | 1,045,855 |
| Open | 96.58 |
| Previous Close | 94.60 |
| Day's Range | 91.00 - 97.96 |
| 52-Week Low | 78.46 |
| 52-Week High | 176.99 |
| Beta | 2.89 |
| Holdings | 151 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
271.14% of assets| Name | Symbol | Weight |
|---|---|---|
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 63.50% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 46.44% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 36.62% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 34.28% |
| DREYFUS GOVT CASH MAN INS | n/a | 26.63% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 26.27% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 15.45% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 10.06% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 8.77% |
| DREYFUS TRSRY SECURITIES CASH MGMT | n/a | 3.13% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
| Dec 21, 2023 | $0.20968 | Dec 29, 2023 |
| Sep 19, 2023 | $0.0404 | Sep 26, 2023 |
| Jun 21, 2023 | $0.180 | Jun 28, 2023 |
| Dec 23, 2019 | $0.1062 | Dec 31, 2019 |
News
Top Performing Leveraged/Inverse ETFs: 01/26/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Buy LABU: Biotech Sector Benefits From Lower Interest Rates And AI
Seeking Alpha Quant rates LABU as a “HOLD”, but I rate it as a “BUY”. Markets expect the first interest rate cut at the September Fed meeting. LABU has strong momentum and benefits from lower interest...
LABU: A Really Bad Drift
Leveraged ETFs have a non-linear, unpredictable behavior. Here is a drift dashboard with 22 leveraged ETFs. Direxion Daily S&P Biotech Bull 3X Shares ETF is the worst. LABU is an instrument for season...
LABU: Buy As The Biotech Sector Starts A New Bull Market (Technical Analysis)
Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology...
LABU: Tool For Swing Traders
The Direxion Daily S&P Biotech Bull and Bear 3X Shares (LABU) provides 3x daily exposure to a biotechnology index. Levered ETFs like LABU are designed for short-term trading and may suffer tracking er...
Breakouts Everywhere As Buffett Moves To Record High $157 Billion Cash
Warren Buffett's Berkshire Hathaway has reached record-high levels of cash, with $157 billion on hand, exceeding Disney's market capitalization. The last time Buffett held record cash levels was in la...
LABU And LABD: Another Attractive Double-Short Pairs Trade
Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode ov...
Biopharma Bounce-Back: From Policy Pains To Profitable Plains
The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail ...
LABU: A Levered ETF Doomed From The Start
The Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) is a high-risk, leveraged ETF that aims to yield three times the performance of the S&P Biotechnology Select Industry Index. The biotech sector...
LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund
LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU can work for medium term returns if two requirement...
Leveraged Biotech ETFs: Hold LABU, Sell LABD
SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, th...
LABU: Leveraged Biotech ETF Review
Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap a...
LABU: Opportunities For Gains Exist If Bought And Sold At Correct Price
LABU is more volatile than unleveraged funds, due to its 3-times investments in the derivatives of stocks listed in its benchmark index. During the past 4 months, biotechnology stocks performed quite ...
LABU Continues In Uptrend (Technical Analysis)
During July, LABU traded in a narrow range. In August, its uptrend has resumed. We expect that LABU's uptrend has a long way to go.
LABU And The Biotechs Look Ready To Outperform (Technical Analysis)
I believe small- and mid-cap biotech bottomed in May through June and has outperformed the broader market since then. Biotech continues to show strong relative outperformance versus the market and mos...
Leveraged Biotech ETFs: Buy LABU, Sell LABD
Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%.
LABU: This 3X Leveraged Bull ETF Fails To Raise Any Optimism
Since my last coverage in the previous quarter, LABU has been on a free fall for the past 12 weeks and also recorded a huge loss over the past 6. 3X funds like LABU have the highest expense ratio and ...
LABU: A 3X Leveraged ETF Best Avoided
Extremely poor, mostly high negative return since LABU's inception.
LABU - A Compelling Biotech Trade
LABU, a triple ETF (3x) from Direxion Funds, tracks the S&P Biotechnology Select Industry Index.
LABU: Now Best Near-Term Cap Gain Among Leveraged-Long ETFs Say Market-Maker Hedging Deals
MMs “fill” Institutional huge Block-Trades by borrowing otherwise unavailable shares, sell short, hedge the short risk, ultimately cover shorts in accommodative market periods. Short-risk hedge-seller...
LABU Provides Leveraged Access For Risk-Taking Investors
Direxion Daily S&P Biotech Bull 3X Shares ETF is a biotechnology focused passive fund. The fund is aimed at providing three times the daily performance of its benchmark index.
ETF/ETN Breakouts Week 39 - September 2021: Short-Term Funds To Give You An Edge
This is the first public release of the weekly ETF/ETN forecast article, highlighting some strong sectors, index funds and commodities for your consideration. This report goes out weekly with live dai...
ARK: Cathie Wood And The Exquisite Art Of Tail Gunning
ARK Active ETFs are worth the management fee. Structured Lookback is introduced.